Q1 EPS Estimates for Nuvectis Pharma Cut by Roth Capital

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Equities researchers at Roth Capital cut their Q1 2025 earnings estimates for Nuvectis Pharma in a research note issued to investors on Tuesday, February 25th. Roth Capital analyst J. Aschoff now expects that the company will earn ($0.28) per share for the quarter, down from their previous estimate of ($0.23). The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share. Roth Capital also issued estimates for Nuvectis Pharma’s Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.08) EPS, FY2026 earnings at ($1.12) EPS and FY2027 earnings at $1.33 EPS.

Separately, HC Wainwright dropped their price target on Nuvectis Pharma from $21.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday.

Nuvectis Pharma Stock Performance

Shares of NASDAQ:NVCT opened at $6.71 on Friday. The firm has a market capitalization of $129.64 million, a PE ratio of -5.78 and a beta of 0.22. Nuvectis Pharma has a 52-week low of $4.44 and a 52-week high of $12.10. The firm has a fifty day moving average of $6.22 and a 200 day moving average of $6.41.

Nuvectis Pharma (NASDAQ:NVCT) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.08).

Insider Transactions at Nuvectis Pharma

In related news, major shareholder Marlio Charles Mosseri bought 17,000 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was bought at an average cost of $4.70 per share, for a total transaction of $79,900.00. Following the acquisition, the insider now directly owns 2,612,000 shares of the company’s stock, valued at $12,276,400. The trade was a 0.66 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders acquired 261,500 shares of company stock worth $1,300,825. 35.78% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in NVCT. Baldwin Wealth Partners LLC MA raised its holdings in Nuvectis Pharma by 104.4% during the 4th quarter. Baldwin Wealth Partners LLC MA now owns 355,961 shares of the company’s stock valued at $1,926,000 after buying an additional 181,831 shares during the last quarter. Marshall Wace LLP increased its position in shares of Nuvectis Pharma by 191.0% in the fourth quarter. Marshall Wace LLP now owns 124,571 shares of the company’s stock valued at $674,000 after acquiring an additional 81,757 shares during the period. Iridian Asset Management LLC CT purchased a new stake in shares of Nuvectis Pharma during the third quarter worth about $348,000. Geode Capital Management LLC grew its stake in shares of Nuvectis Pharma by 49.8% in the third quarter. Geode Capital Management LLC now owns 79,716 shares of the company’s stock worth $501,000 after purchasing an additional 26,489 shares during the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new position in Nuvectis Pharma during the 4th quarter valued at about $135,000. Institutional investors own 96.77% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.